Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AKAO

Achaogen (AKAO) Stock Price, News & Analysis

Achaogen logo

About Achaogen Stock (NASDAQ:AKAO)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.11
$0.11
52-Week Range
N/A
Volume
N/A
Average Volume
3.34 million shs
Market Capitalization
$7.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Achaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.

Receive AKAO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achaogen and its competitors with MarketBeat's FREE daily newsletter.

AKAO Stock News Headlines

Harry R Weller's Net Worth
$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
Ravi Viswanathan's Net Worth
AKAOQ Historical Data
See More Headlines

AKAO Stock Analysis - Frequently Asked Questions

Achaogen Inc (NASDAQ:AKAO) released its quarterly earnings data on Monday, August, 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by $0.19. The biopharmaceutical company earned $2.56 million during the quarter, compared to the consensus estimate of $1.49 million. Achaogen had a negative net margin of 2,136.94% and a negative trailing twelve-month return on equity of 357.49%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Achaogen investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Associated British Foods (ABF), Chaarat Gold (CGH), AMC Entertainment (AMC) and Ciena (CIEN).

Company Calendar

Last Earnings
8/06/2018
Today
4/25/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AKAO
Fax
N/A
Employees
206
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-186,510,000.00
Net Margins
-2,136.94%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$8.73 million
Price / Cash Flow
N/A
Book Value
($0.13) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$7.03 million
Optionable
Optionable
Beta
0.78
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:AKAO) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners